# OnCo record tepotinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tepotinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tepotinib" ;
  schema:name "Tepotinib"@en ;
  schema:alternateName "MSC2156119"@en, "EMD 1214063"@en, "Tepmetko" ;
  schema:description "Tepotinib is a once-daily targeted pill for lung cancers driven by a MET exon 14 skipping mutation, and the MET inhibitor NICE funds in England."@en ;
  schema:url <https://onco.cc/drugs/tepotinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tepotinib> ;
  schema:citation <https://doi.org/10.1056/NEJMoa2004407>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=tepotinib>, <https://www.nice.org.uk/guidance/ta789> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule MET tyrosine kinase inhibitor" ;
  onco:approval "US 2021: Metastatic NSCLC with MET exon 14 skipping alterations", "EU 2022: Advanced NSCLC with MET exon 14 skipping alterations after immunotherapy or platinum chemotherapy", "JP 2020: Unresectable advanced or recurrent NSCLC with MET exon 14 skipping", "England (NICE) 2022: Advanced non-small-cell lung cancer with MET exon 14 skipping alterations" ;
  onco:acceleratedApproval "US 2021-02-03: Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations." ;
  onco:acceleratedApprovalConfirmed "US 2024-02-15: Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations." ;
  onco:related <https://onco.cc/biomarkers/met-ex14/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/capmatinib/> ;
  onco:companies <https://onco.cc/companies/merck-kgaa/> ;
  onco:trials <https://onco.cc/trials/nct02864992/> .